The company, founded in 2020 and based in Paris, France, leverages single-cell analysis to identify new targets and precision medicines for difficult-to-treat conditions. They have a multi-disciplinary team with in-house computational capabilities and are backed by Institut Curie and Home Biosciences. With their proprietary platform and single-cell computational software, One Biosciences analyzes disease-causing agents and provides treatment solutions, focusing on developing therapeutics for challenging diseases. The company was co-founded by Magali Richard, David Schilansky, and Céline Vallot.